Magnesium and Seizure Threshold: Evidence in Epilepsy

Magnesium and seizure threshold matter clinically because neuronal firing depends on tightly controlled ion gradients and excitatory signaling. Yet the evidence base must be interpreted carefully: magnesium is established in specific acute-care contexts, while the provided references do not include human randomized trials showing that an oral magnesium supplement prevents seizures or treats epilepsy.

Magnesium and Seizure Threshold: What the Research Landscape Actually Shows

The central evidence-based conclusion is that low magnesium can increase neuromuscular excitability, but this does not prove that routine supplementation raises seizure threshold in people with epilepsy. “Seizure threshold” describes the level of physiologic stress or neuronal excitability at which abnormal synchronized brain activity is more likely to produce a seizure. Magnesium is biologically relevant to that threshold because it participates in membrane stability, ATP-dependent ion transport, and glutamatergic signaling.

The supplied literature is not an epilepsy-treatment evidence set. Abbasi et al. (2012) studied primary insomnia in 46 older adults, not epilepsy. Tarleton et al. (2017) studied 126 adults with mild-to-moderate depressive symptoms, not seizure frequency. Boyle et al. (2017) systematically reviewed magnesium supplementation for subjective anxiety and stress, while Gröber et al. (2015) reviewed magnesium’s broader roles in prevention and therapy.

That distinction is important. A mechanism can be plausible, a nutrient deficiency can deserve correction, and magnesium may still be inappropriate to present as an anticonvulsant supplement without direct clinical trials. People with epilepsy should not substitute magnesium for prescribed antiseizure medication, alter medication doses, or interpret a normal supplement label as evidence of seizure-control benefit.

There are also several kinds of magnesium-related clinical questions that are often conflated:

• Acute magnesium treatment: medical use in defined hospital settings is different from self-directed oral supplementation.
• Correction of deficiency: appropriate when hypomagnesemia is documented or strongly suspected, particularly if symptoms or risk factors are present.
• Epilepsy prevention or adjunctive treatment: requires seizure-specific human evidence, which is not supplied by the listed references.
• General sleep, stress, or mood support: may affect seizure-relevant lifestyle factors indirectly, but is not the same as a demonstrated increase in seizure threshold.

Magnesium status itself is not always straightforward to assess. DiNicolantonio et al. (2018) discuss subclinical magnesium deficiency and the limitations of relying exclusively on serum magnesium, since most body magnesium is stored in bone and soft tissue rather than circulating in blood. That does not mean every nonspecific symptom indicates deficiency; it means interpretation should consider diet, medicines, gastrointestinal losses, kidney function, and the clinical picture. For a broader discussion, see Magnesium Deficiency: 10 Signs You May Be Low and Why Blood Tests Miss It.

How Magnesium Influences Seizure Threshold at the Molecular Level

Magnesium helps restrain excessive neuronal excitation by supporting electrical stability and modulating excitatory receptors. At resting membrane potentials, magnesium acts as a voltage-dependent blocker within the NMDA-type glutamate receptor channel. When neurons depolarize sufficiently, this block is relieved, allowing calcium influx and contributing to excitatory neurotransmission. This is one reason magnesium has a credible mechanistic relationship to neuronal excitability.

That mechanism should not be oversimplified. NMDA receptor signaling is essential for normal synaptic function, learning, and plasticity; it is not simply “bad” or “good.” Seizures arise from complex networks involving inhibitory GABAergic signaling, glutamatergic excitation, sodium and calcium channels, inflammation, sleep deprivation, genetics, structural brain changes, medication adherence, and epilepsy syndrome. Magnesium is one component of this physiology, not a single switch that determines whether a seizure occurs.

Magnesium is also required for hundreds of enzyme reactions and is functionally linked to ATP. ATP is usually present in cells as a magnesium-ATP complex, so low magnesium can affect energy-dependent processes, including sodium-potassium ATPase activity and ion homeostasis. When ion gradients are poorly maintained, neurons may become more prone to inappropriate firing. Gröber et al. (2015) describes magnesium’s broad physiologic role in neuromuscular function and cellular metabolism.

Another relevant pathway is calcium regulation. Magnesium and calcium often have opposing effects on cellular excitability: calcium entry can promote neurotransmitter release and intracellular signaling, while magnesium helps regulate calcium handling and receptor activity. This does not justify taking large magnesium doses to “block calcium.” Both minerals are necessary, and excessive magnesium can be dangerous, especially when renal clearance is impaired.

Sleep and stress are also clinically relevant to the conversation about magnesium and seizure threshold. Poor sleep is a common seizure trigger for many people, and stress can worsen perceived seizure burden or contribute to missed meals, missed medication, and sleep disruption. Abbasi et al. (2012) found that magnesium supplementation was associated with improved subjective insomnia measures in a small placebo-controlled study of older adults, but that population and outcome cannot be generalized to epilepsy. Boyle et al. (2017) similarly concluded that the magnesium-and-anxiety literature had limitations in quality and heterogeneity.

The practical inference is modest: correcting a true deficiency and supporting sleep or stress management may be reasonable parts of overall health care, but neither is proof of direct antiseizure efficacy. Readers interested in the broader excitability context can also review Magnesium and Nerve Function: The Mineral's Role in Neuropathy and Nerve Excitability.

Magnesium Forms and Seizure-Threshold Questions: What Dose Comparisons Can—and Cannot—Tell You

The best oral magnesium form for seizure threshold has not been established in epilepsy trials from the provided reference list. Product forms differ in elemental magnesium content, gastrointestinal tolerance, and the compounds paired with magnesium, but those differences should not be mistaken for evidence that one form prevents seizures. Dose decisions should begin with the reason for treatment, laboratory findings when available, concurrent medicines, and kidney function.

Clinical context	Magnesium approach discussed in the literature	Study population and duration	What it can tell us about epilepsy
Primary insomnia	500 mg magnesium daily	46 older adults; 8-week double-blind placebo-controlled trial	Suggests a sleep-related research signal in that population; does not measure seizures or establish an antiseizure dose.
Mild-to-moderate depression	248 mg elemental magnesium daily as magnesium chloride	126 adults; 6-week randomized clinical trial	Addresses mood symptoms, not epilepsy, seizure frequency, EEG outcomes, or medication interactions.
Stress and anxiety symptoms	Multiple formulations and doses across studies	Systematic review of heterogeneous studies	Evidence quality and design variation prevent an epilepsy-specific dose recommendation.
General magnesium physiology	Dietary intake and clinically appropriate correction of deficiency	Review evidence	Supports biologic plausibility, not a replacement for epilepsy-specific clinical trials.

Abbasi et al. (2012) used 500 mg of magnesium daily in older adults with primary insomnia, reporting changes in sleep-related outcomes. Tarleton et al. (2017) used 248 mg of elemental magnesium daily as magnesium chloride for six weeks in adults with depression and reported improved PHQ-9 and GAD-7 symptom scores. These are useful examples of studied oral doses, but they should not be repurposed as dosing instructions for epilepsy.

Magnesium glycinate is commonly selected because many people find it easier on the gastrointestinal tract than some other forms. That is a tolerability consideration, not evidence that glycinate crosses into the brain in a clinically meaningful way or raises seizure threshold more effectively than other forms. The same caution applies to claims about magnesium L-threonate; the available discussion is more relevant to cognition than seizure treatment. See Magnesium L-Threonate: The Form That Crosses the Blood-Brain Barrier and Its Cognitive Evidence for that narrower evidence question.

PEPAX Magnesium Glycinate with Astragalus & B6 may be considered by adults seeking a magnesium glycinate product in a broader stress-support routine, but it should not be positioned as an epilepsy therapy. Vitamin B6 and astragalus add separate biologic considerations, including potential medication interactions and condition-specific risks. A clinician or pharmacist should review the full ingredient list alongside antiseizure medicines before use.

Who May Benefit When Magnesium and Seizure Threshold Are a Clinical Concern?

The people most likely to benefit from magnesium assessment are those at risk of deficiency, not everyone with epilepsy automatically. The clinical goal is to identify and correct a meaningful contributor to abnormal excitability or general ill health, while preserving proven epilepsy care. Individualized assessment is especially important because both low magnesium and excessive magnesium can create problems.

Potential higher-risk groups include people with chronic diarrhea or malabsorption, prolonged vomiting, very restricted diets, poorly controlled diabetes, heavy alcohol use, or medicines that can affect magnesium balance. Diuretics and long-term acid-suppressing therapy are common examples that warrant a medication review, although a treating clinician must determine relevance for an individual patient. DiNicolantonio et al. (2018) emphasizes that low magnesium intake and subclinical deficiency may be more common than routine testing suggests.

People with epilepsy who have recurrent seizures should prioritize the established causes that deserve urgent review: medication adherence, recent medication changes, sleep loss, alcohol or recreational drug exposure, acute illness, fever, metabolic disturbance, pregnancy-related care, and changes in seizure pattern. Magnesium is only one item among possible electrolyte and metabolic considerations. New seizures, seizure clusters, injury, prolonged confusion, pregnancy, or seizures lasting five minutes or longer require urgent medical evaluation rather than a supplement trial.

Older adults may deserve particular attention because they may have lower dietary intake, more medications, and reduced kidney function. However, reduced kidney function also increases the risk that supplemental magnesium accumulates. Symptoms of excess magnesium can include nausea, weakness, low blood pressure, lethargy, slowed reflexes, and—in severe cases—dangerous cardiac or respiratory effects.

For people whose concern is indirectly related to sleep, stress, or mood, the evidence is separate from seizure outcomes. The small insomnia trial by Abbasi et al. (2012) and the depression trial by Tarleton et al. (2017) provide condition-specific information, not epilepsy guidance. It is reasonable to discuss sleep quality and psychological stress in epilepsy care because both can affect quality of life and trigger management, but it is not evidence that magnesium will reduce seizure frequency.

Practical Decisions About Magnesium and Seizure Threshold

A cautious plan treats magnesium as a nutrient and possible deficiency issue, not as a self-prescribed anticonvulsant. The most useful next step is usually a medication-and-risk-factor review with a clinician who knows the person’s seizure history. This is particularly important when adding a multi-ingredient product, changing several supplements at once, or interpreting symptoms that could signal either a seizure-related problem or an electrolyte disturbance.

• Do not stop, skip, or reduce antiseizure medication because of magnesium supplementation.
• Ask a clinician whether serum magnesium, calcium, sodium, potassium, kidney function, and glucose testing are appropriate when seizures change or deficiency is suspected.
• Review all prescription medicines, over-the-counter products, antacids, laxatives, and supplements to avoid duplicate magnesium exposure.
• Use a measured dose from one product rather than combining several magnesium-containing products without calculating total intake.
• Separate magnesium from medicines when a pharmacist advises it, because mineral supplements can reduce absorption of some drugs.
• Track seizure timing, sleep, missed doses, illness, alcohol exposure, menstrual cycle where relevant, and supplement changes in the same diary.

A seizure diary is particularly useful because it reduces hindsight bias. If a person starts magnesium during a period of better sleep, fewer missed doses, and less stress, an apparent improvement cannot automatically be attributed to the supplement. Conversely, if seizures worsen after starting a supplement, the timing deserves clinical review but does not alone establish causation.

Dietary magnesium remains a sensible foundation for most people who can safely consume it: legumes, nuts, seeds, whole grains, leafy greens, and some mineral waters contribute meaningful amounts. Food-based approaches also provide fiber, potassium, and other nutrients that isolated supplements do not. For people managing appetite issues, gastrointestinal disease, renal disease, or specialized diets, individualized nutrition advice is preferable to generic targets.

PEPAX Magnesium Glycinate with Astragalus & B6 is best approached as a supplement product for appropriate adults—not as a claim of seizure prevention. If a customer has epilepsy, a history of unexplained loss of consciousness, kidney disease, pregnancy, or multiple medications, clinician approval should come before beginning it. That framing is more consistent with the current evidence than promising a direct effect on epilepsy.

Magnesium and Seizure Threshold: Bottom Line for Epilepsy

Magnesium has a credible physiologic role in neuronal excitability, but the provided evidence does not demonstrate that oral magnesium supplements raise seizure threshold or reduce seizures in people with epilepsy. The strongest practical use is identifying and correcting deficiency risk under clinical guidance while maintaining evidence-based antiseizure treatment. Confidence in this conclusion is high because it reflects the limits of the available human studies rather than extending sleep, stress, or mood data beyond what those studies measured.

---

References

1. Abbasi B, et al. "The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial." Journal of Research in Medical Sciences. 2012;17(12):1161–1169. [Source]
2. Boyle NB, et al. "The Effects of Magnesium Supplementation on Subjective Anxiety and Stress — A Systematic Review." Nutrients. 2017;9(5):429. [Source]
3. Gröber U, et al. "Magnesium in Prevention and Therapy." Nutrients. 2015;7(9):8199–8226. [Source]
4. DiNicolantonio JJ, et al. "Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis." Open Heart. 2018;5(1):e000668. [Source]
5. Tarleton EK, et al. "Role of magnesium supplementation in the treatment of depression: A randomized clinical trial." PLOS ONE. 2017;12(6):e0180067. [Source]

---

---